---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-035974"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:45:28.219242+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ocugen reports Q2 net loss $0.04/sh; advances OCU400 Phase 3 trial, raises $32.6M

## Summary
- Net loss per share $0.04 in Q2 2024 versus $0.10 in Q2 2023; total operating expenses $16.6M, down from $24.0M.
- Cash, equivalents, restricted cash $16.0M at June 30, 2024, down from $39.5M at Dec 31, 2023.
- Subsequent to quarter end, closed public offering with net proceeds $32.6M, extending cash runway into Q3 2025.
- Actively dosing patients in OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa; FDA approved expanded access program.
- OCU410 Phase 2 initiated for geographic atrophy; OCU410ST high-dose dosing; OCU200 clinical hold discussions ongoing.

## SEC filing metadata
- accession: 0001628280-24-035974
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828024035974/0001628280-24-035974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828024035974/ocgn-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-035974
- JSON: https://secwatch.observer/filing/0001628280-24-035974.json
- Plain text: https://secwatch.observer/filing/0001628280-24-035974.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.